ENTITY

Lonza Group (LONN SW)

26
Analysis
Health CareSwitzerland
Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. The company works with healthcare customers to develop, manufacture and commercialize medical treatments and technologies to treat patients against a range of diseases. Founded in the Swiss Alps, Lonza now operates across Europe, North America, South America, Asia and Oceania.
more
bullishWuXi XDC Cayman
08 Nov 2023 02:15

WuXi XDC IPO Valuation Analysis: Premium Multiples Reflect 100%+ Top-Line Growth

WuXi XDC set terms for an upcoming IPO in Hong Kong. The company plans to raise ~$470M, and the IPO price range implies a market cap of ~$3B at the...

Logo
603 Views
Share
bullishWuXi XDC Cayman
07 Nov 2023 11:39

WuXi XDC Cayman IPO - Decent Upside from IPO Range, Bulk of the Deal Taken up by Marquee Investors

WuXi XDC Cayman (1877628D HK) is looking to raise US$470m in its Hong Kong IPO. In this note, we will look at the deal dynamics and share our final...

Logo
655 Views
Share
bullishWuXi XDC Cayman
07 Nov 2023 06:08

WuXi XDC IPO Preview: The Rapid Rise of The Business In The Global ADC and Bioconjugate Market

WuXi XDC filed to go public in Hong Kong. A rare combination of explosive growth and profitability makes the IPO attractive for investors

Logo
453 Views
Share
bullishWuXi XDC Cayman
06 Nov 2023 14:19

WuXi XDC Cayman Pre-IPO - BULL/BEAR Scenario Considerations for Valuations

WuXi XDC Cayman (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we share our updated thoughts on...

Logo
422 Views
Share
bullishWuXi XDC Cayman
31 Oct 2023 11:00

WuXi XDC Cayman Pre-IPO - PHIP Updates - Margins Remain Depressed Although Growth Still Strong

WuXi XDC Cayman Inc (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we discuss WXDC’s PHIP updates.

Logo
394 Views
Share
x